Drug intelligence / Profile preview

sofosbuvir + GS-0938 + ribavirin

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral

Overview

This is a three-drug **oral combination regimen** investigated for the treatment of chronic hepatitis C virus (HCV) infection. **Sofosbuvir** is a nucleotide analog NS5B polymerase inhibitor that acts as a chain terminator, blocking HCV RNA replication. **GS-0938** (also known as PSI-352938) is another nucleotide analogue inhibitor of HCV NS5B RNA-dependent RNA polymerase. **Ribavirin** is a synthetic nucleoside analog with broad-spectrum antiviral activity, frequently used in combination with other agents for HCV. The combination aims to provide an interferon-free therapy for HCV by combining two direct-acting antivirals with different resistance profiles and complementary mechanisms, along with ribavirin.

Other names: sofosbuvir + GS-352938 + ribavirin

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on sofosbuvir + GS-0938 + ribavirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sofosbuvir + GS-0938 + ribavirin.

Explore the full profile